The history and promise of gene therapy: A scientist's view from the front lines of basic and applied clinical research

Genetic Engineering and Biotechnology News

Volumn 31, Issue 17, 2011, Pages

  Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH;

GENE THERAPY;

EID: 84862917870     PISSN: 1935472X     EISSN: 19378661     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Muul, L.M., et al., Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood, 2003. 101(7), 2563-9.
2. Crystal, R.G., et al., Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet, 1994. 8(1), 42-51.
3. Zabner, J., et al., Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell, 1993. 75(2), 207-16.
4. Zuckerman, J.B., et al., A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther, 1999. 10(18), 2973-85.
5. Yang, Y., et al., Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol, 1995. 69(4), 2004-15.
6. Berns, K.I., Parvoviridae: The Viruses and Their Replication, in Fields Virology 1996.
7. Moss, R.B., et al., Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther, 2007. 18(8), 726-32.
8. Manno, C.S., et al., Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006. 12(3), 342-7.
9. Hacein-Bey-Abina, S., et al., Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med, 2002. 346(16), 1185-93.
10. Hacein-Bey-Abina, S., et al., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003. 302(5644), 415-9.
11. Acland, G.M., et al., Gene therapy restores vision in a canine model of childhood blindness. Nat Genet, 2001. 28(1), 92-5.
12. Maguire, A.M., et al., Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008. 358(21), 2240-8.
13. Bainbridge, J.W., et al., Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008. 358(21), 2231-9.
14. Cideciyan, A.V., et al., Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther, 2009. 20(9), 999-1004.
15. Naldini, L., et al., In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 1996. 272(5259), 263-7.
16. Cartier, N., et al., Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 2009. 326(5954), 818-23.
17. Gao, G.P., et al., Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 2002. 99(18), 11854-9.
18. Gao, G., et al., Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004. 78(12), 6381-8.
19. Gao, G., et al., Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A, 2003. 100(10), 6081-6.
20. Ponder, K.P., Hemophilia gene therapy: a Holy Grail found. Mol Ther, 2011. 19(3), 427-8.
21. Forsayeth, J.R. and K.S. Bankiewicz, AAV9: Over the Fence and Into the Woods. Mol Ther, 2011. 19(6), 1006-7.